Invex Therapeutics (ASX:IXC) Cash Payments: A$-1.60 Mil (TTM As of Dec. 2025)


ASX:IXC Invex Therapeutics Ltd ASX:IXC
38 GF Score
Price A$0.11
! 1 Warning Sign
View Full Analysis

What is Invex Therapeutics Cash Payments?

Invex Therapeutics ASX:IXC 38 Cash Payments is A$-1.60 Mil as of Dec. 2025. GuruFocus rates ASX:IXC with a GF Score™ of 38/100. The stock has 1 warning sign investors should review.

Invex Therapeutics's Cash Payments for the six months ended in Dec. 2025 was A$-0.84 Mil.

Invex Therapeutics's Cash Payments for the trailing twelve months (TTM) ended in Dec. 2025 was A$-1.60 Mil.

Invex Therapeutics Cash Payments Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Cash Payments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Cash Payments Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cash Payments
Get a 7-Day Free Trial -1.84 -3.64 -8.13 -4.15 -1.11

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Payments Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.69 -1.45 -0.36 -0.76 -0.84
ASX:IXC
38GF Score
Invex Therapeutics Ltd ASX:IXC
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invex Therapeutics Cash Payments Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Cash Payments represents cash flow paid from operating activities in the direct cash flow method.

GuruFocus lists following items in "Cash Payments" section for non-financial companies:
Payments to Suppliers for Goods and Services
Payments on Behalf of Employees
Other Cash Payments from Operating Activities

Cash Payments for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-1.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Payments →
What does a Cash Payments of A$-1.60 Mil mean?
Invex Therapeutics (ASX:IXC) has a Cash Payments of A$-1.60 Mil as of Dec. 2025. Cash Payments represents cash paid from operating activities in direct cash flow method. View historical data for Invex Therapeutics and its competitors.
Is Invex Therapeutics' Cash Payments too high?
Invex Therapeutics' current Cash Payments is A$-1.60 Mil. Overall, Invex Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Invex Therapeutics' Cash Payments compare to VRTX and REGN?
Invex Therapeutics' Cash Payments of A$-1.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Payments for a Biotechnology company?
A good Cash Payments depends on the Biotechnology industry context. However, Cash Payments should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Payments mean?
A high Cash Payments can signal that a stock is expensive relative to its fundamentals. Cash Payments represents cash paid from operating activities in direct cash flow method. View historical data for Invex Therapeutics and its competitors. Invex Therapeutics's current Cash Payments is A$-1.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Cash Payments of A$-1.60 Mil. The current Cash Payments is A$-1.60 Mil. Invex Therapeutics' overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Payments calculated?
Cash Payments is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Cash Payments is A$-1.60 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
38GF Score

Get the complete analysis for ASX:IXC

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price